Literature DB >> 10860881

Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

L K Hallak1, P L Collins, W Knudson, M E Peeples.   

Abstract

Respiratory syncytial virus (RSV) is an important human respiratory pathogen, particularly in infants. Glycosaminoglycans (GAGs) have been implicated in the initiation of RSV infection of cultured cells, but it is not clear what type of GAGs and GAG components are involved, whether the important GAGs are on the virus or the cell, or what the magnitude is of their contribution to infection. We constructed and rescued a recombinant green fluorescent protein (GFP)-expressing RSV (rgRSV) and used this virus to develop a sensitive system to assess and quantify infection by flow cytometry. Evaluation of a panel of mutant Chinese hamster ovary cell lines that are genetically deficient in various aspects of GAG synthesis showed that infection was reduced up to 80% depending on the type of GAG deficiency. Enzymatic removal of heparan sulfate and/or chondroitin sulfate from the surface of HEp-2 cells also reduced infection, and the removal of both reduced infection even further. Blocking experiments in which RSV was preincubated with various soluble GAGs revealed the relative blocking order of: heparin > heparan sulfate > chondroitin sulfate B. Iduronic acid is a component common to these GAGs. GAGs that do not contain iduronic acid, namely, chondroitin sulfate A and C and hyaluronic acid, did not inhibit infection. A role for iduronic acid-containing GAGs in RSV infection was confirmed by the ability of basic fibroblast growth factor to block infection, because basic fibroblast growth factor binds to GAGs containing iduronic acid. Pretreatment of cells with protamine sulfate, which binds and blocks GAGs, also reduced infection. In these examples, infection was reduced by pretreatment of the virus with soluble GAGs, pretreatment of the cells with GAG-binding molecules, pretreatment of the cells with GAG-destroying enzymes or in cells genetically deficient in GAGs. These results establish that the GAGs involved in RSV infection are present on the cell rather than on the virus particle. Thus, the presence of cell surface GAGs containing iduronic acid, like heparan sulfate and chondroitin sulfate B, is required for efficient RSV infection in cell culture. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860881     DOI: 10.1006/viro.2000.0293

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  109 in total

1.  The central conserved cystine noose of the attachment G protein of human respiratory syncytial virus is not required for efficient viral infection in vitro or in vivo.

Authors:  Michael N Teng; Peter L Collins
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

2.  Cleavage at the furin consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus fusion protein are dispensable for virus replication in cell culture.

Authors:  Gert Zimmer; Karl-Klaus Conzelmann; Georg Herrler
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

3.  A flow cytometry-based assay to assess RSV-specific neutralizing antibody is reproducible, efficient and accurate.

Authors:  M Chen; J S Chang; M Nason; D Rangel; J G Gall; B S Graham; J E Ledgerwood
Journal:  J Immunol Methods       Date:  2010-08-19       Impact factor: 2.303

4.  Identification of internal sequences in the 3' leader region of human respiratory syncytial virus that enhance transcription and confer replication processivity.

Authors:  David R McGivern; Peter L Collins; Rachel Fearns
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium.

Authors:  Liqun Zhang; Alexander Bukreyev; Catherine I Thompson; Brandy Watson; Mark E Peeples; Peter L Collins; Raymond J Pickles
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 6.  Animal pneumoviruses: molecular genetics and pathogenesis.

Authors:  Andrew J Easton; Joseph B Domachowske; Helene F Rosenberg
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

Review 7.  Development and clinical applications of novel antibodies for prevention and treatment of respiratory syncytial virus infection.

Authors:  Asuncion Mejias; Cristina Garcia-Maurino; Rosa Rodriguez-Fernandez; Mark E Peeples; Octavio Ramilo
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

Review 8.  Structural, antigenic and immunogenic features of respiratory syncytial virus glycoproteins relevant for vaccine development.

Authors:  José A Melero; Vicente Mas; Jason S McLellan
Journal:  Vaccine       Date:  2016-09-28       Impact factor: 3.641

9.  Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus.

Authors:  Srikanth Kota; Ahmed Sabbah; Te Hung Chang; Rosalinda Harnack; Yan Xiang; Xiangzhi Meng; Santanu Bose
Journal:  J Biol Chem       Date:  2008-06-20       Impact factor: 5.157

10.  Role of nucleolin in human parainfluenza virus type 3 infection of human lung epithelial cells.

Authors:  Santanu Bose; Mausumi Basu; Amiya K Banerjee
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.